This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Zydus Pharmaceuticals
Zydus Pharmaceuticals, a prominent player in the global pharmaceutical industry, is headquartered in the United States, with significant operations across North America, Europe, and Asia. Founded in 1995, the company has established itself as a leader in the development and manufacturing of generic and specialty pharmaceuticals, focusing on areas such as oncology, cardiovascular health, and diabetes management. Zydus Pharmaceuticals is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that includes injectables, biosimilars, and over-the-counter medications. The company has achieved notable milestones, including numerous FDA approvals and a strong presence in the biosimilars market, positioning it as a trusted name in healthcare. With a dedication to improving patient outcomes, Zydus continues to expand its reach and impact within the pharmaceutical landscape.
DitchCarbon Score
How does Zydus Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zydus Pharmaceuticals's score of 21 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zydus Pharmaceuticals's reported carbon emissions
In 2023, Zydus Pharmaceuticals reported a total Scope 1 and Scope 2 emission intensity of approximately 0.0000153 kg CO2e per million of turnover, reflecting their operational emissions. For 2024, this figure increased to about 0.0000386 kg CO2e per million of turnover. These emissions data are cascaded from Zydus Pharmaceuticals (USA) Inc., indicating a corporate family relationship. Currently, Zydus Pharmaceuticals has not disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. There are no commitments to the Science Based Targets initiative (SBTi) or other climate pledges noted in the available data. The absence of detailed emissions data for Scope 1, Scope 2, and Scope 3 suggests that the company may still be in the early stages of formalising its climate strategy. As a current subsidiary of Zydus Pharmaceuticals (USA) Inc., Zydus Pharmaceuticals is positioned within a broader corporate framework that may influence its future climate commitments and emissions reporting.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zydus Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
